Przejdź do zawartości
Merck

Przejdź do

438185

Lovastatin

Lovastatin, CAS 75330-75-5, is an anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

Synonim(y):

Lovastatin, Mevinolin, MK-803, L-Type Calcium Channel Blocker IV

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok
Gabaryty przesyłkiSKUDostępnośćCena netto
25 mg

Przewidywany termin wysyłki28 maja 2026zKuehne + Nagel Sp. z o.o.

1230,00 zł

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C24H36O5
Numer CAS:
Masa cząsteczkowa:
404.54
UNSPSC Code:
41116107
NACRES:
NA.77
MDL number:
Assay:
≥95% (HPLC)
Form:
powder
Storage condition:
OK to freeze, protect from light

1230,00 zł


Przewidywany termin wysyłki28 maja 2026Szczegóły


Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


Quality Segment

description

Merck USA index - 14, 5586

assay

≥95% (HPLC)

form

powder

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

white to off-white

solubility

ethanol: 25 mg/mL, DMSO: 50 mg/mL

shipped in

ambient

storage temp.

2-8°C

SMILES string

O1[C@@H](C[C@H](CC1=O)O)CC[C@@H]2[C@H]3[C@H](C[C@H](C=C3C=C[C@@H]2C)C)OC(=O)[C@H](CC)C

InChI

1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1

InChI key

PCZOHLXUXFIOCF-BXMDZJJMSA-N

General description

An anti-hypercholesterolemic agent and an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that blocks a series of biological events including: activation of p21ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF. This product requires activation for use in cell synchronization studies and in cell-free assay systems for HMG-CoA studies.
An anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Has been shown to block a series of biological events including: the activation of p21ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes; the farnesylation of p21ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin); and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase through inhibition of proteasome. Has recently been shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and to block the transcription of type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF. This product requires activation for use in cell synchronization studies and in cell-free assay systems for HMG-CoA studies.

Biochem/physiol Actions

Cell permeable: no
Primary Target
Activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Product does not compete with ATP.
Reversible: no

Preparation Note

Following reconstitution aliquot, flush with an inert gas, and freeze (-20°C). Stock solutions, in high quality DMSO or ethanol are stable for up to 1 month at -20°C.

Other Notes

Rao, S., et al. 1999. Proc. Natl. Acad. Sci. USA96, 7197.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem. 271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys. 326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.
Jakobisiak, M., et al. 1991. Proc. Natl. Acad.Sci. USA88, 3628.
Keyomarsi, K., et al. 1991. Cancer Res.51, 3602.
Mendola, C.E., and Backer, J.M. 1990. Cell Growth Differ. 1, 499.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Carcinogenic / Teratogenic (D)
Ta strona może zawierać tekst przetłumaczony maszynowo.

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 1

Ta pozycja
PHR12851370600Y0001136
Lovastatin United States Pharmacopeia (USP) Reference Standard

USP

1370600

Lovastatin

form

powder

form

-

form

-

form

-

assay

≥95% (HPLC)

assay

-

assay

-

assay

-

manufacturer/tradename

Calbiochem®

manufacturer/tradename

-

manufacturer/tradename

USP

manufacturer/tradename

EDQM

Quality Level

200

Quality Level

300

Quality Level

-

Quality Level

-

storage temp.

2-8°C

storage temp.

-10 to -25°C

storage temp.

-

storage temp.

−20°C

solubility

ethanol: 25 mg/mL, DMSO: 50 mg/mL

solubility

-

solubility

-

solubility

-


Still not finding the right product?

Explore all of our products under Lovastatin


pictograms

Health hazard

signalword

Warning

Hazard Classifications

Carc. 2 - Repr. 2

Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów


Produkty

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.






Numer pozycji handlu globalnego

SKUNUMER GTIN
438185-25MG04055977186956

Questions

Reviews

No rating value

Active Filters